LBPH - Longboard Pharmaceuticals - Stock & Dividends

Longboard Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, is dedicated to creating groundbreaking treatments for neurological diseases. By leveraging cutting-edge science, the company aims to improve the lives of patients suffering from debilitating neurological conditions.

The company's lead candidate, bexicaserin (LP352), has successfully completed a Phase 1b/2a clinical trial, demonstrating its potential as a treatment for seizures associated with developmental and epileptic encephalopathies. This innovative therapy has the potential to address a significant unmet medical need, offering new hope to patients and their families.

In addition to LP352, Longboard Pharmaceuticals is also developing LP659, an S1P receptor modulator with broad therapeutic potential for various neurological diseases. This promising compound has the potential to revolutionize the treatment landscape for a range of conditions, from neurodegenerative disorders to inflammatory diseases.

Formerly known as Arena Neuroscience, Inc., the company rebranded as Longboard Pharmaceuticals Inc. in October 2020, marking a new chapter in its mission to transform the field of neurological medicine. With its headquarters in La Jolla, California, Longboard Pharmaceuticals Inc. was incorporated in 2020 and is poised to make a significant impact in the biopharmaceutical industry.

For more information about Longboard Pharmaceuticals Inc. and its innovative pipeline, please visit their website at https://www.longboardpharma.com.